Gene therapy injection aims to halt blindness from dry AMD
NCT ID NCT07158775
First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 34 times
Summary
This study tests a new gene therapy called BS01 for people with advanced dry age-related macular degeneration (AMD) that causes blind spots. The treatment is given as an injection into the eye and aims to slow or stop further vision loss. The trial involves 40 adults aged 50 to 85 and will first check safety, then measure how well it preserves eyesight compared to a sham procedure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY (GA) SECONDARY TO DRY AGE-RELATED MACULAR DEGENERATION (AMD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NJ Retina
RECRUITINGEdison, New Jersey, 08820, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.